The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-c and tumor necrosis factor (TNF)-a synergistically upregulated FAT10 expression in liver and colon cancer cells 10-to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-c-and TNF-adependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.
The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-c and tumor necrosis factor (TNF)-a synergistically upregulated FAT10 expression in liver and colon cancer cells 10-to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-c-and TNF-adependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment. Oncogene (2008) 27, 6068-6074; doi:10.1038 /onc.2008 published online 23 June 2008 Keywords: FAT10; ubiquitin-like modifiers; hepatocellular carcinoma; colon carcinoma; interferon-g Hepatocellular carcinomas (HCCs) and colon carcinoma (CC) are among the most frequent malignant tumors worldwide. Because of the aggressive growth and the lack of effective treatment options, the 5-year survival of HCC patients is extremely low (Kern et al., 2002) . A protein that has been recently proposed to contribute to HCC and CC tumor development is the ubiquitin-like modifier FAT10 (Lee et al., 2003) . FAT10, which had been initially named 'diubiquitin' or 'ubiquitin D', is an 18 kDa protein consisting of two ubiquitin-like domains (Fan et al., 1996) . FAT10 bears a free diglycine motif at the C terminus, which is used for isopeptide linkage to so far unidentified target proteins (Raasi et al., 2001; Chiu et al., 2007) . Many properties of FAT10 point at a function in the immune system. First, FAT10 is encoded in the major histocompatibility complex class I region close to the HLA-F gene that led to the assignment of its present name HLA-F-associated transcript 10 (Liu et al., 1999) . Second, FAT10 is induced synergistically by interferon (IFN)-g and tumor necrosis factor (TNF)-a (Liu et al., 1999; Raasi et al., 1999) . Third, the basal expression of FAT10 is the highest in lymphoid organs like thymus, spleen, lymph nodes and fetal liver (Lee et al., 2003; Canaan et al., 2006) . Fourth, FAT10 becomes upregulated upon the maturation of dendritic cells (DC; Bates et al., 1997) and, finally, FAT10-deficient mice show a hypersensitivity to lipopolysaccharide (LPS; Canaan et al., 2006) . Although all these properties are consistent with a role of FAT10 in the immune system, its precise biological function remains to be determined. Striking is the observation that an inducible expression of FAT10 in mouse fibroblasts caused caspase-dependent apoptosis (Raasi et al., 2001 ), which was also described for human renal tubular epithelial cells (Ross et al., 2006) and HeLa cells (Liu et al., 1999) .
As FAT10 induced apoptosis in cells, it was surprising that northern blot analysis of FAT10 mRNA revealed an overexpression in 90% of HCC and in over 80% of colon, uterus and ovary cancers (Lee et al., 2003) . On the basis of these data, it was proposed that FAT10 may be involved in the development of these malignancies. Consistent with this hypothesis was that FAT10 interacted noncovalently with the spindle checkpoint protein MAD2 during mitosis (Liu et al., 1999; Ren et al., 2006) . During overexpression of FAT10 in the CC cell line HCT116 for several months a higher degree of variability in chromosome number was noted, which is a hallmark of many cancers. Moreover, wild-type p53 transcriptionally downregulated FAT10 mRNA expression that might contribute to upregulation of FAT10 in cancers (Zhang et al., 2006) . Although all these data are consistent with the notion that FAT10 may promote tumorigenesis, no causal relationship has been established.
In this study we have investigated whether the induction of FAT10 is a consequence of a proinflammatory immune response against these tumors. This hypothesis is founded on the induction of FAT10 by IFN-g and TNF-a and on the finding that approximately 65% of HCC cases express several IFNresponsive and apoptosis-related genes and show a high number of tumor-infiltrating lymphocytes (Breuhahn et al., 2004) . Previously we have shown by northern analysis that the expression of FAT10 mRNA is synergistically inducible by IFN-g and TNF-a in the CC line SW620 (Raasi et al., 1999) . To investigate whether FAT10 induction also occurs in HCC cells, we treated four HCC cell lines (HepG2, Huh-7, PLC/PRF5 and Hep3B) as well as SW620, HeLa and HEK293T cells with IFN-g alone, with TNF-a alone or with both cytokines together for 16 h and the content of FAT10 mRNA was determined by quantitative real-time RT-PCR. As shown in Figure 1a , the induction of FAT10 mRNA by IFN-g and TNF-a ranged from 10-to 100-fold in all cell lines investigated, which was similar to the FAT10 upregulation observed in monocyte-derived DCs upon the induction of maturation with CD40L, LPSor polyI:C (Legler et al., 2006; Supplementary Table 1) . The upregulation of FAT10 expression by toll-like receptor ligands seems to be specific for DC because the treatment of human monocytes with LPS or cytosinephosphate-guanine oligonucleotides did not induce FAT10 expression in spite of an enhancement in interleukin-1b production (data not shown). When we determined the FAT10 mRNA levels in a panel of mouse organs by real-time RT-PCR it appeared that FAT10 was most prominently expressed in the thymus and lymph nodes followed by the intestine and the spleen ( Figure 1b) . As FAT10 expression in liver, uterus and ovaries is more than 100-fold lower than in thymus or lymph nodes it is possible that lymphocyte infiltration will significantly contribute to elevated FAT10 expression levels in tumors of these tissues.
Previously, northern blot analysis of 23 HCC samples has led to the conclusion that FAT10 is overexpressed in 90% of the samples (Lee et al., 2003) . To obtain more quantitative information on FAT10 overexpression in HCC we performed a real-time RT-PCR analysis of 51 validated human HCC tissues as well as two normal human liver samples that served as the basis for calculating the degree of FAT10 overexpression. As shown in Figure 2a , the expression of FAT10 mRNA was quite inhomogeneous. Setting the threshold for FAT10 overexpression at a factor of two, we obtained FAT10 overexpression in 72% of the cases. The highest degrees of overexpression ranged between 45-and 65-fold, which is similar to what we observed in HCC lines ( Figure 1a ). The etiology of HCC among our sample collection comprised 6 cases of chronic alcohol abuse, 10 cases of chronic hepatitis B virus infection, 23 cases of chronic hepatitis C virus infection and 1 case of genetic hemochromatosis whereas for the rest of the cases the etiology was unknown. The degree of FAT10 expression did not correlate with any of the aforementioned etiologies and neither with histological tumor grade. Given that about 65% of HCC samples express IFNstimulated genes (Breuhahn et al., 2004) , we decided to investigate if there is a correlation of FAT10 overexpression with the expression of the IFN-g/TNF-ainducible proteasome subunit LMP2. The LMP2 mRNA expression was upregulated twofold or higher in 63% of the HCC samples ( Figure 2b ). The LMP2 induction varied from 5-to 40-fold, which is a typical result also observed after IFN-g stimulation in vitro (Khan et al., 2001) . Interestingly, the HCC samples that overexpressed FAT10 also expressed LMP2 except for tumor 5 where FAT10 expression but no LMP2 expression was detected. We performed a correlation analysis between the C t values for FAT10 and LMP2 real-time RT-PCR data, and the computed Spearman's correlation coefficient r was 0.699 with Po0.001 (Figure 2c ), indicating a significant correlation between FAT10 and LMP2 expression in HCC samples.
To test a second type of carcinoma reported to overexpress FAT10, we performed a similar real-time The HCC lines HepG2, Huh-7, PLC/PRF5 and Hep3B as well as the colon carcinoma (CC) line SW620, the cervix carcinoma line HeLa, and the human embryonal kidney line HEK293T were treated with IFN-g (200 U/ml, Roche, Mannheim, Germany), TNF-a (400 U/ml, Roche) or both cytokines for 16 h. FAT10 mRNA levels were determined by real-time RT-PCR and calculated relative to unstimulated cells and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. All real-time PCR expression data were analysed using the Excel-based program REST (relative expression software tool; Pfaffl et al., 2002) . Columns represent mean values of at least three independent experiments. Error bars represent standard error. RNA was prepared from cells using a NucleoSpin RNAII kit (Macherey-Nagel, Du¨ren, Germany) according to the manufacturer's protocol. For the synthesis of single-stranded cDNA from pure total RNA the Reverse Transcription System kit (Promega) was used. Quantitative real-time RT-PCR was performed with the LightCycler instrument (Roche) using the LightCycler FastStart DNA Master SYBR Green I (Roche) reaction mix with primers specific for FAT10 (forward: ttgtttcttgtggagtcaggtg, reverse: agtaagttgccctttctgatgc) and GAPDH (forward: gaaggtgaaggtcggagtc, reverse: gaagatggtgatgggatttc). All PCR efficiencies obtained from four serial dilutions were above 95% and real-time PCR reactions were performed in triplicate. Amplification of the correct product was confirmed by a melting point curve analysis followed by agarose gel electrophoresis. (b) Quantification of FAT10 mRNA levels in different mouse tissues. FAT10 mRNA levels in the indicated organs of C57BL/6 mice were determined by real-time RT-PCR as described above and calculated relative to FAT10 mRNA content in brain and normalized to hypoxanthine guanine phosphoribosyl transferase (HPRT-1) expression. Columns represent mean values of three independent experiments. Error bars represent standard error. C57BL/6 mice were bred at the animal facility of Constance University and treated in accordance with institutional guidelines. Primers used for cDNA amplification were mouse HPRT (forward: tggacaggactgaaagacttg, reverse: ccagcaggtcagcaaagaactta) and mouse FAT10 (forward: gggattgacaaggaaaccacta, reverse: ttcacaacctgcttcttaggg).
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RT-PCR analysis with 15 tissue samples of CC. For each of the carcinomas a biopsy of healthy colon tissue from the same patient was available on which FAT10 and LMP2 overexpression was based. The basal expression of FAT10 was higher in normal colon tissue as compared to healthy liver samples, which is in accordance with our analysis of mouse organs (Figure 1b) . Setting a threshold of two for significant overexpression, we scored 8 of 15 carcinomas (53%) to overexpress FAT10 but the extent of FAT10 (Figure 2d ). For CC, an even more stringent correlation of FAT10 and LMP2 expression levels was observed with a Spearman's correlation coefficient of r ¼ 0.826 and Po0.001 (Figure 2e ). Taken together, the strong correlation of FAT10 and LMP2 overexpression in HCC and CC strongly suggests that FAT10 overexpression is a consequence of a proinflammatory immune response in the tumor microenvironment. So far FAT10 overexpression has been assessed only on mRNA level (Lee et al., 2003) . As mRNA and protein levels do not necessarily correlate, we investigated FAT10 protein expression in HCC samples. The analysis of FAT10 expression is not trivial as FAT10 is rapidly degraded (Hipp et al., 2004) and becomes covalently conjugated to target proteins (Raasi et al., 2001; Chiu et al., 2007) . Accordingly, we failed to detect FAT10 in HCC tumor lysates by plain western analysis whereas the proteasome subunit iota (a1), which we used for normalization of the lysates, was readily detectable. To enhance the FAT10 signal we first immunoprecipitated FAT10 from HCC lysates and From the analysis of seven HCC samples, of which sufficient material was available for this procedure, it emerged that those HCC that expressed abundant FAT10 mRNA (HCC 22, 28 and 31) also expressed the intact FAT10 protein whereas normal liver and HCC tissues lacking FAT10 mRNA overexpression did not contain detectable amounts of FAT10 protein (Figure 3) . Other than the monomeric FAT10 band we did not obtain any bands that might correspond to putative FAT10 conjugates, which is probably due to rapid proteasomal degradation resulting in low steadystate levels of FAT10 conjugates.
Although the overexpression of FAT10 mRNA in HCC and CC has been well documented, it has never been investigated whether FAT10 was mutated. We sequenced Fat10 cDNAs from 10 HCC samples and 5 CC samples which all overexpressed FAT10 mRNA (Table 1 ). Compared to the FAT10 sequence retrieved from a human DC library (accession number Y12653), different nucleotides were observed at positions 198, 203 and 479 in some of the HCC samples. However, all three-sequence variations can be found as single nucleotide polymorphisms in noncancerous tissues in the National Center for Biotechnology Information database as well. We hence conclude that there is no evidence for oncogenic or loss of function mutations in the FAT10 sequences of FAT10 overexpressing HCC.
To further assess whether FAT10 may contribute to oncogenesis in a cell-autonomous manner, we tested the consequences of FAT10 expression in the classical NIH3T3 colony formation assay. NIH3T3 fibroblasts were transiently transfected with expression vectors encoding human or murine FAT10 as well as with the empty vector pTHamp (negative control) and the E7 oncogene of human papilloma virus (HPV) strain 16 alone or with HPV16 E6 and E7 together (positive controls). All vectors were co-transfected with an expression construct for human CD4 that allowed the magnetic purification of successfully transfected cells. The expression of neither murine nor human FAT10 enabled any transfected cells to grow in soft agar within 1 month whereas expression of HPV16 E6 alone or E6 and E7 together yielded 150 and 180 colonies per 5000 seeded cells, respectively ( Figure 4) . As FAT10 transfection did not transform NIH3T3 cells in spite of validation of FAT10 mRNA expression by RT-PCR (data not shown) we conclude that FAT10 has no active transforming potential.
On the basis of the significant overexpression of FAT10 in over 80% of gynecological and gastrointestinal cancers, Lee et al. (2003) have proposed that FAT10 may be involved in carcinogenesis. At first glance these results were unexpected given that the ectopic expression of FAT10 has been shown by three independent groups to induce apoptotic cell death in at least three different cell lines (Liu et al., 1999; Raasi et al., 2001; Ross et al., 2006) . This conceptual conflict was our incentive to reinvestigate FAT10 mRNA overexpression in a larger Figure 1a and overexpression was calculated relative to two normal liver samples and normalized to 18S rRNA expression. In addition to an oligo(dT) primer the gene specific 18S rRNA-RT primer gagctggaattaccgcggct (Zhu and Altmann, 2005) was used for reverse transcription of 1 mg total RNA. The reaction was carried out using the manufacturer's protocol except that the step at 42 1C was prolonged to 1 h instead of 15 min. Primers for amplification of 18S rRNA were forward: gaggtagtgacgaaaaataacaat, reverse: ttgccctccaatggatcct. All data are expressed as mean values of triplicate measurements from the same sample. Error bars represent standard error. (c) Spearman's analysis of correlation between C t values of FAT10 and the interferon (IFN)-g-and tumor necrosis factor (TNF)-a-inducible proteasome subunit LMP2 in HCC samples. The coefficient of correlation r is 0.6999 with Po0.0001. The Spearman's correlation coefficient r was computed with FAT10 and LMP2 C t values with a two-tailed P-value. Analysis was performed with the statistical software Prism 4 (GraphPad Software, San Diego, CA, USA). samples. An anti-FAT10 immunoprecipitation was performed with tissue from normal liver and seven HCC samples and the precipitates were analysed by western blotting using the same FAT10-specific antibody (upper panel). FAT10 protein is only detectable in samples where FAT10 mRNA is overexpressed (see Figure 2a ). Western analysis of total lysates with an antibody specific for the proteasome subunit iota (a1, from Dr Klaus Scherrer, Paris) was used as loading control. Tissues were lysed in 20 mM Tris (pH 7.8), 150 mM NaCl, 0,1% Triton X-100, supplemented with protease-inhibitors (phenylmethylsulphonyl fluoride (PMSF) 100 mM, aprotinin 5 mg/ml, pepstatin 1 mM). Immunoprecipitation was performed overnight at 4 1C with 40 ml protein-A beads (Sigma, Taufkirchen, Germany) and 15 ml anti-FAT10 polyclonal antibody (Hipp et al., 2005) . Samples were separated on 12% SDS-polyacrylamide gel electrophoresis (PAGE) and analysed by western blot probed with the same anti-FAT10 antibody.
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S Lukasiak et al panel of HCC specimen by quantitative real-time RT-PCR. We agree that FAT10 is overexpressed in HCC and CC but setting the threshold for significant overexpression to a factor of two, we found only 72% of HCC and 53% of CCs to overexpress FAT10. A striking property of FAT10 is its synergistic inducibility with IFN-g and TNF-a. Considering a previous transcriptome analysis, which found 65% of HCC tissues to overexpress genes known to be inducible by type I and type II interferons (Breuhahn et al., 2004) , we hypothesized that FAT10 overexpression in HCC is due to stimulation with proinflammatory cytokines. First we showed in four HCC cell lines that the strong induction by IFN-g and TNF-a, which we found by northern analysis in the carcinoma line SW620 (Raasi et al., 1999) , is also true in all analysed HCC cell lines (Figure 1 ). This finding argues against the possibility that the responsiveness to IFN-g and TNF-a is lost in the majority of HCC tissues. To assess the state of IFN-g and TNF-a induction in HCC and CC samples we chose to quantitatively assess the mRNA expression of the IFN-g-and TNF-a-inducible proteasome subunit LMP2. LMP2 is a suitable marker for monitoring IFN-g and TNF-a stimulation in tissues as it is characterized by a very low basal expression in the liver (Stohwasser et al., 1997) and a strong upregulation upon an antiviral immune response. Experiments in IFN-gdeficient mice demonstrated that this upregulation of LMP2 is dependent on IFN-g (Khan et al., 2001 ). We found a very strong correlation of FAT10 and LMP2 expression both in HCC and CC samples (Figure 2) , which, based on current knowledge, can only be explained by a joint upregulation of FAT10 and LMP2 by proinflammatory cytokines. Our present and previous data do not agree with the finding that HCC tissues that overexpress FAT10 do not express other genes responsive to an immunological response (Lee et al., 2003) . This conclusion was based on the analysis of HCC from four patients and may need confirmation in a larger set of tumors. Lee et al. (2003) have analysed HCC tissue overexpressing FAT10 by in situ hybridization and found that lower FAT10 signals were also detected in other cell types surrounding HCC cells including immune cells. This finding argues clearly in favor of elevated FAT10 expression being a consequence of cytokine production by infiltrating leukocytes. The argument that no FAT10 expression was found in healthy liver tissue from the same patient is not necessarily in conflict with this possibility as the liver is a large organ and an immune response may be confined to the vicinity of the tumor lesion. The notion that nonmalignant cells in the surrounding of HCC lesions also upregulated FAT10 expression was very recently confirmed in a study on chemically induced HCC in mice where FAT10-positive hepatocytes were found located close to the tumor and blood vessels (Oliva et al., 2008) . However, no evidence for chromosomal aberrations was found in FAT10-positive HCC T and C HCC 50
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The FAT10 cDNAs from 10 HCC samples and 5 CC samples found to overexpress FAT10 (see Figure 2 ) were sequenced. Single nucleotide polymorphisms found at the nucleotide positions 198, 203 and 479 are shown. An empty field indicates that the same nucleotide as in the FAT10 cDNA from human DC (accession number Y12653) was found. Amino-acid changes due to the respective polymorphisms are indicated at the bottom. cDNA samples were PCR-amplified with PFU polymerase (Promega, Du¨bendorf, Switzerland) using FAT10 sequencing primers (forward: cagcaaagctggacaaacac, reverse: ccatcccacccaaatcttac) and then sequenced by GATC Inc. (Konstanz, Germany) using the dideoxynucleotide sequencing method. All samples were verified by sequencing sense and anti-sense strands.
Figure 4 FAT10 does not function as an oncogene in the NIH3T3 colony formation assay. NIH3T3 cells were co-transfected with the CD4 expression vector (pMACS-hCD4, Miltenyi, Bergisch Gladbach, Germany) together with either empty vector pTHamp (control), or HPVÀ16 E7 or HPVÀ16 E6 þ HPVÀ16 E7 (inserted via 5 0 HindIII/ 3 0 XbaI into pTHamp, respectively), or murine mFAT10 (PCRgenerated His/HA-mFAT10 was inserted via 5 0 ApaI/3 0 NotI into pCMV-vector, Invitrogen, Karlsrube, Germany), or human hFAT10 (pcDNA3.1-HA-hFAT10; Raasi et al., 2001) using Effectene transfection reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Transgene expression was verified by RT-PCR. The cells were analysed by flow cytometry on a FACScan flow cytometer (BD Biosciences, Heidelberg, Germany) 1 day after transfection and 5000 CD4-positive cells were seeded (suspended in the same medium as used for the base layer) onto a precast base layer consisting of 5 ml Dulbecco's modified Eagle's medium (DMEM)/ 10% fetal calf serum (FCS) with 1% soft agar in 50 mm Petri dishes. Soft agar cultures were incubated at 37 1C/5% CO 2 adding 0.5 ml complete DMEM/10% FCS once per week. After 4 weeks all foci located within a 9 cm 2 field of the soft agar plate were counted. Data given are the mean of foci numbers of the triplicates±standard deviation. The assay has been repeated once with similar outcome.
FAT10 upregulation by proinflammatory cytokines S Lukasiak et al cells in this model over an induction period of 8-14 months. It is therefore not clear whether the chromosomal instability found for a FAT10 transfected CC line during 11 months of in vitro cultivation is physiologically relevant (Ren et al., 2006) .
To investigate whether the function of FAT10 may be linked to carcinogenesis it was important to find out if there are mutations in the FAT10 open-reading frame and whether the enhanced FAT10 mRNA expression is accompanied with elevated FAT10 protein expression. The heterozygous point mutations found at the nucleotide positions 203 and 479 of the FAT10 open-reading frame were present in several entries of expressed sequence tag, single nucleotide polymorphism and genomic libraries generated from nontumorous material, indicating that they are single nucleotide polymorphisms that are not linked to tumor development. These data rule out that FAT10 is mutated in tumors to gain oncogenic properties and they are inconsistent with FAT10 being a tumor repressor that has acquired mutations to function as a dominant-negative variant. Owing to a lack of material we could only analyse three of the HCC specimen overexpressing FAT10 by immunoprecipitation and western blotting but in all these tissues, monomeric FAT10 protein of the expected molecular mass but no obvious FAT10 conjugates could be detected.
In conclusion, we have shown that the overexpression of FAT10 in HCC and CC is a consequence of a proinflammatory immune response in almost all cases and that there is no reason to propose that FAT10 contributes to carcinogenesis in a cell-autonomous manner. In fact, in NIH3T3 colony formation assays FAT10 failed to exert transforming activity (Figure 4) . Our data do not rule out that other factors such as transcriptional reprogramming, the formation of Mallory-Denk bodies (Oliva et al., 2008) or the loss of p53 may contribute to FAT10 overexpression to a minor extent but the striking coexpression of FAT10 and LMP2 can not be explained if these other factors would be major determinants of FAT10 expression.
